This is a StreetInsider.com Premium Only Page

Aclaris Therapeutics (ACRS) – Major News

Nov 6, 2023 07:23 AM Aclaris Therapeutics (ACRS) Tops Q3 EPS by 7c

Aug 7, 2023 07:01 AM Aclaris Therapeutics (ACRS) Tops Q2 EPS by 3c, misses on revenue

Feb 23, 2023 08:44 AM Aclaris Therapeutics (ACRS) Tops Q4 EPS by 4c

Nov 8, 2022 07:09 AM Aclaris Therapeutics (ACRS) Tops Q3 EPS by 9c

May 10, 2022 07:08 AM Aclaris Therapeutics (ACRS) Tops Q1 EPS by 9c

Feb 24, 2022 07:02 AM Aclaris Therapeutics (ACRS) Misses Q4 EPS by 1c

Feb 22, 2021 12:33 PM Aclaris Therapeutics (ACRS) Hires Bankers to Explore Potential Sale - Source

Oct 10, 2019 04:03 PM Aclaris Therapeutics (ACRS) Announces Divestiture of RHOFADE

Jul 30, 2019 04:39 PM Aclaris Therapeutics (ACRS) Phase 2 Clinical Trial of ATI-501 Oral in Patients with Alopecia Areata Met Primary Endpoint

Mar 18, 2019 07:08 AM Aclaris Therapeutics (ACRS) Reports In-Line Q4 EPS, Revenues Beat

Mar 12, 2018 07:04 AM Aclaris Therapeutics (ACRS) Tops Q4 EPS by 17c, Beats on Revenues

Aug 8, 2017 07:27 AM Aclaris Therapeutics (ACRS) Reports Q2 Loss of $0.56/Share

Nov 15, 2016 04:09 PM Aclaris Therapeutics (ACRS) Announces Two A-101 Phase 3s Met All Primary, Secondary Endpoints as SK Treatment

Aug 11, 2016 07:05 AM Aclaris Therapeutics (ACRS) Reports Q2 Loss of $0.62/Share

Mar 23, 2016 04:04 PM Aclaris Therapeutics (ACRS) Reports Q4 Loss of $0.28/Share

Oct 7, 2015 10:07 AM Aclaris Therapeutics (ACRS) IPO Opens 9% Higher

Oct 7, 2015 08:52 AM Aclaris Therapeutics (ACRS) IPO Prices at $11, Well Below Expected Range